A Go-to-Market Strategy Fails When the Market Has Not Formed Yet

Published
September 2, 2026
Last updated
October 20, 2026
Table of contents

A go-to-market strategy fails in medtech when it executes well against a market nobody defined. You have FDA clearance, clinical data, and funding. You hire sales, run campaigns, and the deals still stall.

The gap sits upstream of execution. Category design, messaging, and narrative never happened before go-to-market started, and no sales hire can supply them. I've seen the same pattern across 400+ episodes of The State of MedTech.

Key Takeaways

  • A go-to-market strategy is the fourth of four parts in market engineering, after category design, messaging, and narrative.
  • Some medtech companies have raised hundreds of millions of dollars, a couple of them over a billion, and have nothing to show because the category was never designed.
  • Messaging is the first part to break, because it sits downstream from the category.
  • FDA-clearance buzz lasts a week or two, with aftereffects for a couple of months, and none of it validates the market.
  • Early adopters buy possibility, and the early majority buys category clarity, so the two groups need different proof.
  • On the chasm episode I described how Intuitive Surgical started in cardiac surgery, then focused on radical prostatectomy and won that segment before it expanded.

What Is a Go-to-Market Strategy in Medtech?

A go-to-market strategy is the plan for turning a cleared product into repeatable revenue. It covers who you sell to, what you say, and how sales and marketing work together. In medtech it only works after the market understands the category the product belongs to.

Harvard Business School Online describes it as "a detailed plan of how your startup will reach its target customers effectively and efficiently". That definition holds in software, where buyers already know the category.

In medtech, the plan also has to explain the market to the customer. So the definition needs one more clause. A medtech go-to-market strategy reaches the right buyers after the market understands the problem, the category, and why your approach should be the default.

The checklists that dominate this search are written for general B2B and software buyers. Founders follow them literally, then wonder why nothing converts.

I go deeper on the market-formation side in why building the market comes before the sales team.

What Are the Five Pillars of a Go-to-Market Strategy?

A go-to-market strategy rests on a target market, an offer, pricing, channels, and a launch motion. Every standard framework lists some version of these. They work when the category is established and buyers already know what you sell.

Medtech changes what each pillar means.

Target market. The buyer is rarely one person. A surgeon, a hospital administrator, and a purchasing committee each judge you on different things.

Offer. It has to land with the clinician and with the person who pays. A clinical result tells a surgeon the device works. An economic case tells the hospital why it should pay for it.

Pricing. Price depends on reimbursement, and reimbursement is often unsettled when you launch.

Channels. Sometimes the channel doesn't exist yet. No rep firm wants to carry an unproven product in a category buyers can't name.

Launch motion. A launch creates attention. Attention is a different thing from demand, and the gap between them is where most plans stall.

Run them on an undefined category and each one inherits the confusion.

Medtech Founders Build a Go-to-Market Strategy Before the Category Exists

Wax seal stamping a blank, unfinished blueprint, symbolizing launching before the category is defined

Founders build go-to-market first because it's the only part of the sequence they can see. Sales hires and campaigns feel tangible, and category work doesn't. So the order flips, and the market never learns what the company is.

Product work has a process. You freeze the design, run the studies, and earn the clearance. It's tangible and it's sequential.

The market side has no equivalent. Bruce Cleveland calls the space between initial product release and real traction the traction gap.

In my view, companies stall in it because they change method. They engineer the product with rigor, then improvise everything else.

I covered this on a recent episode about how market engineering helps medtech startups raise capital:

"There's a lot of discipline around engineering and developing your product. There's not a lot of discipline and engineering when it comes to thinking about a market."

Market engineering closes that gap. I laid out the formula on the same episode:

"Market engineering equals the sum of these four things. Category design, messaging, narrative, and then go-to-market. And specifically in that order."

Each part gives the next one something to work with. A message needs a category to sit inside. A narrative needs a message to carry. And a sales team needs all three before a buyer can say why they should take the meeting.

I wrote the longer version in the market engineering framework.

How Messaging and Narrative Turn a Defined Category Into Belief

Messaging and narrative turn a defined category into belief. Messaging is your positioning, differentiation, and proof. Narrative is your point of view and the education that gets buyers thinking in your category's language.

Both sit downstream from the category, so both fail when it's unclear.

I covered this on the same episode about raising capital:

"The first thing that usually breaks is messaging because it's downstream from the category."

I saw it firsthand while evaluating startups that week. Most of them hadn't framed a category or redesigned one. They knew their clinical pathway cold, and the questions they got were all about what made them different.

If people have to ask what makes you different, the category work is missing. No amount of copy fixes that.

So build the messaging on a matrix. Write down who each message is for, what problem it names, and what proof backs it up. Narrative comes next, and it carries that proof, both clinical and economic.

Founders treat these two steps as branding. The go-to-market step depends on both, so skip them and it has nothing to stand on.

A Go-to-Market Strategy Loses to the Incumbent When the Category Is Undefined

Brass compass with its needle spinning without settling, representing a strategy competing against an undefined category

A go-to-market strategy without a defined category defaults into competing against the incumbent. The buyer compares you to the category leader, on the leader's terms, in the leader's language. A bigger budget doesn't change that comparison.

Skipping category design slows the strategy down and puts the company in a fight it can't win.

The better product and the larger team still lose when the buyer can only judge you as a smaller, riskier version of the leader.

I've watched well-funded medtech companies run exactly this play. I described it on the same raising-capital episode:

"There's plenty of companies in our space who've raised hundreds of millions of dollars, a couple of them over a billion dollars, and they have nothing to show. You have to go back and spend that time to think first again, what's the category we're playing in?"

Later in the same conversation I said what happens to a company that skips that step:

"They have nothing to show because they did not think about designing or redesigning their category against the de facto standard incumbent. So guess what happens? The market compares and evaluates that company against the category leader. And guess what happens? You lose every single time."

Category design breaks that comparison. It gives the strategy a different game to play, one where the company sets the terms. I wrote more about it in category design for medtech market leaders.

The companies that break out of this pattern pause the go-to-market strategy, do the category work, and relaunch into a defined market. The pause feels like lost time, but it's usually the fastest way back to growth.

Sales Blames Awareness When a Go-to-Market Strategy Underperforms

Megaphone projecting light into thick fog that absorbs the beam, showing awareness efforts dissolving unheard

When a go-to-market strategy stalls, sales blames awareness and asks for more marketing. That instinct points at the wrong target. More campaigns against an undefined category produce more education calls while closed deals stay flat.

Launch attention makes this worse. A company announces FDA clearance and gets some inbound.

On the raising-capital episode I described how long that lasts, which is a week or two, with aftereffects for a couple of months. Founders read it as validation, and it validates nothing.

I opened my conversation with Nick Damiano, founder of Andromeda Surgical, on autonomous surgery and the future of robotics with this:

"They fail because the market never really forms around them. Clinical validation is not adoption. FDA clearance is not demand. And innovation alone does not create a category."

A go-to-market strategy can't manufacture the demand that category design was supposed to build first. That's why adding headcount rarely fixes a stalled one. A new rep still has to explain the category from scratch on every call.

I made the same point on the raising-capital episode:

"Hiring more salespeople isn't going to fix this. You can't outsell a misdefined market. You just can't do it."

Founders treat slow deals as a hiring problem when the cause is a definition problem.

How Beachhead Focus Helps a Go-to-Market Strategy Cross the Chasm

A go-to-market strategy that tries to win the whole market at once usually wins none of it. The remedy is a beachhead: one small, precise segment, won completely, before you expand.

Early adopters and the early majority need different proof, so a plan that treats them the same stalls between them.

I laid out why on an episode about how medtech startups cross the chasm and scale:

"Early adopters, they buy possibility. Early majority, they buy category clarity."

Early adopters are vision-driven, so a promising device and a strong story can win them. The early majority is pragmatic.

They want proven outcomes, and they need to understand the category before they trust you. I wrote about where that change hits in the technology adoption curve in medtech.

On the same episode, I described the remedy:

"The way you cross the chasm is through focus. You don't win the whole market. You win a small segment at first."

Intuitive Surgical is the example I use. It didn't try to sell every type of surgery at once.

On that episode I described how it started in cardiac surgery, then put its procedures, sales, and resources behind radical prostatectomy. It owned that segment, then expanded.

That's the same principle behind category work. Define the market on your terms, win one segment inside it completely, then expand from proof.

How to Sequence a Go-to-Market Strategy From Category to Launch

Stone foundation blocks stacking in sequence, one suspended above an incomplete base structure

Sequence a go-to-market strategy by defining the category, building the messaging, developing the narrative, and only then launching. Check for repeatable traction after each step. Don't start the launch until the first three hold.

  1. Define the category. Design a new category or redesign an existing one. Name the problem and write down the rules buyers should use to judge you.
  2. Build the messaging. Turn the category into positioning, differentiation, and proof.
  3. Develop the narrative. Add the clinical and economic proof, then teach the market through your point of view.
  4. Launch go-to-market. Align sales and marketing against a market that already understands the problem.

Before step four, set a minimum viable category, the way you'd ship a minimum viable product before you scale.

Test yourself on category, segment, and proof. What category are you in, in one sentence a stranger could repeat? Which segment are you winning first? And what proof does that segment need?

If you're past initial product release, you haven't missed the window. The cost of changing course rises with every hire and every campaign you commit to, so start now.

The founder or CEO should own this. It touches fundraising, early adopters, and commercialization, and delegating it to marketing is how the first three steps get skipped. If you do bring in outside help, I wrote about when external go-to-market help pays off.

For the detail on timing, read how medtech founders should sequence a medical device go-to-market strategy and how a B2B go-to-market strategy should sequence.

What Does All of This Mean for Medtech Founders?

In my experience working with medtech founders, the go-to-market conversation happens too early almost every time. Founders want a plan because it feels like the finish line after years of product development.

But a go-to-market strategy is the last step in market engineering, after category and narrative. Skipping ahead to it moves the same unresolved category work downstream, where it costs more to fix.

Before writing a go-to-market strategy, I ask founders whether a buyer can explain, in their own words, what category this product belongs to and why it matters right now. If the answer is no, the strategy has nothing solid to stand on yet.

Companies that do the category work first spend less on go-to-market, because they aren't paying campaigns to do the education work category design should have handled. The budget reinforces a message the market already half-believes.

On the chasm episode, I explained why the order matters:

"You need to think about market product fit, which means you go and try to understand the market in terms of its needs, its problems, those kind of things, and then figure out a way to build a market around that."

That's market-product fit, and it comes before anything you'd call a launch. Once the category, messaging, and narrative exist, go-to-market becomes the easiest part of the whole sequence.

Frequently Asked Questions

What is the difference between a go-to-market strategy and market engineering?

A go-to-market strategy plans how you reach a market that already exists. Market engineering forms the market first, by defining the category, the problem, and the language buyers use.

In established categories only the first is needed. In medtech, the second usually comes first, because buyers can't evaluate a category they don't recognize.

What is GTM vs sales?

Sales is one part of go-to-market. Go-to-market covers the target segment, the message, the channels, and how sales and marketing work together.

Sales closes deals inside that plan. A company can have a strong sales team and still stall if the plan around it points at a market that hasn't formed.

What is the meaning of GTM?

GTM stands for go-to-market. It refers to the plan for taking a product to its buyers, covering who they are, what you say, and how you reach them.

In medtech it also includes the market work that comes before launch, like category design, messaging, and narrative. Skipping that work is where most medtech plans break.

How do you create a go-to-market strategy for a medtech company?

Define the category, write the messaging, build the narrative, then plan the launch. Name your first customer segment and the clinical and economic proof it needs.

If you can't explain the category in one sentence, go back to step one. Write each step down before you hire a rep or book a campaign.

When should a medtech company build its go-to-market strategy?

Build it after category design, messaging, and narrative are in place, and start those three before initial product release when you can. If you're already past release, start now. The cost of changing course rises with every hire and every campaign you commit to.

Where Should You Go From Here?

If you're doing this yourself. Read the market engineering framework and write your category, first segment, and proof on one page. Then listen to The State of MedTech to hear how other founders defined theirs.

If you want it engineered with you. MarketCraft takes on a small number of medtech teams each quarter, starting with The Market Engineering Audit. It checks whether your gap sits upstream in the category or downstream in sales.

Listen to the Full Conversations

The episodes behind this post are on The State of MedTech. Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialisation strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.

Copied!